ATE350394T1 - Gonokokkenproteine und nukleinsäuren - Google Patents

Gonokokkenproteine und nukleinsäuren

Info

Publication number
ATE350394T1
ATE350394T1 AT02730631T AT02730631T ATE350394T1 AT E350394 T1 ATE350394 T1 AT E350394T1 AT 02730631 T AT02730631 T AT 02730631T AT 02730631 T AT02730631 T AT 02730631T AT E350394 T1 ATE350394 T1 AT E350394T1
Authority
AT
Austria
Prior art keywords
proteins
gonococcial
nucleic acids
gonococcus
meningococcus
Prior art date
Application number
AT02730631T
Other languages
English (en)
Inventor
Maria Rita Fontana
Mariagrazia Pizza
Vega Masignani
Elisabetta Monaci
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE350394T1 publication Critical patent/ATE350394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Seasonings (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02730631T 2001-02-12 2002-02-12 Gonokokkenproteine und nukleinsäuren ATE350394T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103424.8A GB0103424D0 (en) 2001-02-12 2001-02-12 Gonococcus proteins

Publications (1)

Publication Number Publication Date
ATE350394T1 true ATE350394T1 (de) 2007-01-15

Family

ID=9908561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730631T ATE350394T1 (de) 2001-02-12 2002-02-12 Gonokokkenproteine und nukleinsäuren

Country Status (13)

Country Link
US (2) US7504111B2 (de)
EP (2) EP1777233A3 (de)
JP (2) JP2004537977A (de)
AT (1) ATE350394T1 (de)
AU (1) AU2002302921A1 (de)
CA (1) CA2438080C (de)
CY (1) CY1106431T1 (de)
DE (1) DE60217320T2 (de)
DK (1) DK1385876T3 (de)
ES (1) ES2278920T3 (de)
GB (1) GB0103424D0 (de)
PT (1) PT1385876E (de)
WO (1) WO2002079243A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371994C (en) * 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
EP2278007B1 (de) * 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Konservierte Antigene aus Neisseria
CA2373236C (en) * 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP4740738B2 (ja) * 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
ES2410585T3 (es) * 2003-12-19 2013-07-02 F.Hoffmann-La Roche Ag Oligonucleótidos, métodos y kits para detectar Neisseria gonorrhoeae
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0404374D0 (en) * 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
US7357932B2 (en) * 2004-06-16 2008-04-15 Center Of Disease Control Department Of Health Surface protein of Neisseria bacteria
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
US8329884B2 (en) 2004-12-17 2012-12-11 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
EP1858920B1 (de) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteine und nukleinsäuren von meningitis-/sepsis-assoziierten escherichia coli
EP1858919B1 (de) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immungene von uropathogenen escherichia coli
EP1723964A1 (de) * 2005-05-20 2006-11-22 Institut Pasteur Verwendung von Penicillin-bindenden Proteinen, Polynukleotiden oder dagegen gerichteten Antikörpern zur Vorbeugung oder Behandlung von bakteriellen Infektionen
GB0513096D0 (en) 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
EP2357184B1 (de) 2006-03-23 2015-02-25 Novartis AG Imidazochinoxalinverbindungen als Immunmodulatoren
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
PT1862557E (pt) * 2006-05-29 2011-09-01 Bio Rad Pasteur Detecção múltipla em tempo real de três espécies bacterianas responsáveis por doenças sexualmente transmissíveis
EP2044104A2 (de) * 2006-06-29 2009-04-08 Novartis AG Polypeptide aus neisseria meningitidis
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2681921A1 (en) * 2007-03-26 2008-10-02 Commonwealth Scientific And Industial Research Organisation Peptides with anitfungal activity
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
BRPI0821240B8 (pt) 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
CN102066404B (zh) * 2008-04-23 2013-11-13 诺娃细胞科技公司 血管生成肽
US8188250B2 (en) 2008-04-28 2012-05-29 Butamax(Tm) Advanced Biofuels Llc Butanol dehydrogenase enzyme from the bacterium Achromobacter xylosoxidans
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
WO2010027729A2 (en) * 2008-08-25 2010-03-11 Creatv Microtech, Inc. Gonococcal vaccines
EP2326662B1 (de) * 2008-08-28 2016-11-23 The University Of Queensland Mutante bakterielle glycoproteine und verwendung
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
CN102639555B (zh) * 2009-09-24 2015-11-25 加利福尼亚大学董事会 膀胱癌特异性配体肽
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
EP2542257B1 (de) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimierte monoklonale antikörper gegen den gewebefaktorinhibitor (tfpi)
CN102905703B (zh) 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
GB201120634D0 (en) * 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (de) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
GB201211154D0 (en) * 2012-06-22 2012-08-08 Univ Southampton Composition
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
AU2013344571A1 (en) 2012-11-16 2015-06-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US9725701B2 (en) 2013-03-15 2017-08-08 Iowa Corn Promotion Board Prokarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants
WO2014150037A1 (en) * 2013-03-15 2014-09-25 Becton, Dickinson And Company Detection of neisseria gonorrhoeaes
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
GB201319180D0 (en) 2013-10-30 2013-12-11 Mast Group Ltd Nucleic acid probe
GB201416459D0 (en) * 2014-09-17 2014-10-29 Atlas Genetics Ltd Detection method
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
CN104673791A (zh) * 2015-03-10 2015-06-03 普生（天津）科技有限公司 淋球菌ng的特异dna序列
WO2016169027A1 (zh) * 2015-04-23 2016-10-27 深圳华大基因研究院 两种芋螺毒素肽、其制备方法及应用
CA3010905A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
SE541618C2 (en) * 2017-02-24 2019-11-12 Biotome Pty Ltd Novel peptides and their use in diagnosis
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
US10450616B1 (en) 2018-05-09 2019-10-22 Talis Biomedical Corporation Polynucleotides for the amplification and detection of Chlamydia trachomatis
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
EP3897706A4 (de) * 2018-12-21 2022-11-23 Griffith University Zusammensetzungen, verfahren und verwendungen zur auslösung einer immunreaktion
US10954572B2 (en) * 2019-07-25 2021-03-23 Talis Biomedical Corporation Polynucleotides for the amplification and detection of Neisseria gonorrhoeae
WO2021022001A1 (en) * 2019-08-01 2021-02-04 Trustees Of Tufts College Vaccine compositions and methods of selecting antigens
US11891662B2 (en) 2019-12-02 2024-02-06 Talis Biomedical Corporation Polynucleotides for amplification and detection of human beta actin
EP4087593A1 (de) * 2020-01-06 2022-11-16 Evaxion Biotech A/S Impfstoffe, die gegen neisseria gonorrhoeae gerichtet sind
WO2022096596A1 (en) 2020-11-04 2022-05-12 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
EP4366762A1 (de) * 2021-07-05 2024-05-15 Evaxion Biotech A/S Impfstoffe gegen neisseria gonorrhoeae
WO2023082011A1 (en) * 2021-11-11 2023-05-19 Institut National De La Recherche Scientifique Endonucleases that selectively cleave single-stranded nucleic acids and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
GB9820003D0 (en) * 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
FR2785293B1 (fr) * 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria

Also Published As

Publication number Publication date
DK1385876T3 (da) 2007-05-14
US20050260581A1 (en) 2005-11-24
EP1777233A2 (de) 2007-04-25
PT1385876E (pt) 2007-04-30
EP1385876B1 (de) 2007-01-03
WO2002079243A2 (en) 2002-10-10
AU2002302921A1 (en) 2002-10-15
DE60217320D1 (de) 2007-02-15
GB0103424D0 (en) 2001-03-28
CA2438080C (en) 2012-05-01
EP1777233A3 (de) 2009-09-30
WO2002079243A3 (en) 2003-11-13
US7504111B2 (en) 2009-03-17
US20090298099A1 (en) 2009-12-03
US8642050B2 (en) 2014-02-04
CY1106431T1 (el) 2012-01-25
DE60217320T2 (de) 2007-08-30
EP1385876A2 (de) 2004-02-04
ES2278920T3 (es) 2007-08-16
JP2004537977A (ja) 2004-12-24
JP2008263973A (ja) 2008-11-06
CA2438080A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE350394T1 (de) Gonokokkenproteine und nukleinsäuren
CY1110880T1 (el) Αντιγονα neisserial
DK1047784T3 (da) Neissera meningitidis-antigener
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
ATE430207T1 (de) Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
EP1144998A3 (de) Genomische sequenzen von neisseria und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1385876

Country of ref document: EP